1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Industry Attractiveness-Porter's Five Forces Analysis
4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Consumers
4.2.3 Threat of New Entrants
4.2.4 Intensity of Competitive Rivalry
4.2.5 Threat of Substitutes
4.3 Industry Value Chain Analysis
4.4 Industry Policies
4.5 Market Drivers
4.5.1 Increasing Outsourcing Volume by Pharmaceutical Companies
4.5.2 Increasing Investment in R&D
4.6 Market Restraints
4.6.1 Increasing Lead Time and Logistics Costs
4.6.2 Stringent Regulatory Requirements
4.6.3 Capacity Utilization Issues Affecting the Profitability of CMOs
4.7 Analysis of Current Licensing and Business Models in the CMO Industry
4.8 Key Criteria Considered for Selection of CMO
4.9 Coverage on Thin Film Contract Outsourcing

5 ASSESSMENT OF IMPACT OF COVID-19 ON THE PHARMACEUTICAL CMO MARKET

6 MARKET SEGMENTATION
6.1 By Service Type
6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.1.1 Small Molecule
6.1.1.2 Large Molecule
6.1.1.3 High Potency API (HPAPI)
6.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing
6.1.2.1 Solid Dose Formulation
6.1.2.1.1 Tablets
6.1.2.1.2 Others
6.1.2.2 Liquid Dose Formulation
6.1.2.3 Injectable Dose Formulation
6.1.3 Secondary Packaging
6.2 By Geography
6.2.1 North America
6.2.1.1 Segmentation by Service Type
6.2.1.2 Segmentation by Country
6.2.1.2.1 United States
6.2.1.2.2 Canada
6.2.2 Europe
6.2.2.1 Segmentation by Service Type
6.2.2.2 Segmentation by Country
6.2.2.2.1 United Kingdom
6.2.2.2.2 Germany
6.2.2.2.3 France
6.2.2.2.4 Italy
6.2.2.2.5 Rest of Europe
6.2.3 Asia Pacific
6.2.3.1 Segmentation by Service Type
6.2.3.2 Segmentation by Country
6.2.3.2.1 China
6.2.3.2.2 India
6.2.3.2.3 Japan
6.2.3.2.4 Australia
6.2.3.2.5 Rest of Asia Pacific
6.2.4 Latin America
6.2.4.1 Segmentation by Service Type
6.2.4.2 Segmentation by Country
6.2.4.2.1 Brazil
6.2.4.2.2 Mexico
6.2.4.2.3 Argentina
6.2.4.2.4 Rest of Latin America
6.2.5 Middle East and Africa
6.2.5.1 Segmentation by Service Type
6.2.5.2 Segmentation by Country
6.2.5.2.1 United Arab Emirates
6.2.5.2.2 Saudi Arabia
6.2.5.2.3 South Africa
6.2.5.2.4 Rest of Middle East and Africa

7 COMPETITIVE LANDSCAPE - VENDOR MARKET SHARE

8 COMPETITIVE LANDSCAPE
8.1 Company Profiles
8.1.1 Catalent Inc.
8.1.2 Recipharm AB
8.1.3 Jubilant Biosys Ltd.(Jubilant Pharmova Ltd)
8.1.4 Patheon Inc. (Thermo Fisher Scientific Inc.)
8.1.5 Boehringer Ingelheim Group
8.1.6 Pfizer CentreSource (Pfizer Inc.)
8.1.7 Aenova Group
8.1.8 Famar SA
8.1.9 Baxter Biopharma Solutions (Baxter International Inc.)
8.1.10 Lonza Group AG
8.1.11 Tesa Labtec GmbH (TESA SE)
8.1.12 Tapemark
8.1.13 ARX LLC.

9 ANALYSIS OF MAJOR CMOS WHO ARE EQUIPPED TO MANUFACTURE SCHEDULED DRUGS
10 INVESTMENT ANALYSIS
11 FUTURE OF THE GLOBAL PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
12 APPENDIX
12.1 Dosage Formulation Technologies
12.2 Dosage Forms by Route of Administration